Paediatric dolutegravir update
30 April 2019. Related: Conference reports, Paediatric care.
Conference reports
Other cure related studies at CROI 2019
30 April 2019. Related: Conference reports, Cure-related research.
Conference on Retroviruses and Opportunistic Infections (CROI 2019): second reports
28 March 2019. Related: Conference reports.
Maturation inhibitor GSK’232 reduces viral load by –1.5 log at day 10
28 March 2019. Related: Conference reports, Antiretrovirals.
Capsid inhibitor GS-6207 shows potential for 3-monthly injections
28 March 2019. Related: Conference reports, Antiretrovirals.
First phase 1 results from bNAb PGT121 in HIV positive people
28 March 2019. Related: Conference reports, Antiretrovirals.
Dolutegravir/3TC dual ART is as effective at lowest viral load cut-off as triple therapy in GEMINI studies
28 March 2019. Related: Conference reports, Antiretrovirals, Treatment strategies.
Same-day ART is effective in San Francisco Rapid-ART clinic
28 March 2019. Related: Conference reports, Antiretrovirals, Treatment strategies.
Integrase inhibitors and neural tube defects: more data still needed
28 March 2019. Related: Conference reports, Pregnancy.
Double-dose levonorgestrel implant does not overcome interaction with efavirenz
28 March 2019. Related: Conference reports, Women's health, PK and drug interactions.
Efavirenz and rifampicin together reduce levels of injectable contraception
28 March 2019. Related: Conference reports, Women's health, PK and drug interactions.
Bedaquiline and delamanid safe when given together to treat drug resistant TB
28 March 2019. Related: Conference reports, TB coinfection.
Isoniazid preventative therapy in HIV positive pregnant women not linked to poor outcomes
28 March 2019. Related: Conference reports, TB coinfection.
Conference on Retroviruses and Opportunistic Infections (CROI 2019): early reports
12 March 2019. Related: Conference reports.
UK patient likely to be the second person cured of HIV: two further cases at CROI 2019 of HIV remission after allogenic stem cell transplants
12 March 2019. Related: Conference reports, Cure-related research.
Phase 3 results with dual therapy cabotegravir/rilpivirine long-acting injections: ATLAS and FLAIR studies
12 March 2019. Related: Conference reports, Antiretrovirals.
Viral reservoir can explain persistent low level viraemia with good adherence on ART
12 March 2019. Related: Conference reports, Treatment strategies.
Dolutegravir suppresses viral load faster than efavirenz in late pregnancy: results from DolPHIN-2
12 March 2019. Related: Conference reports, Pregnancy.
Raltegravir achieves swifter viral load suppression in pregnancy than efavirenz
12 March 2019. Related: Conference reports, Pregnancy.
New option for PrEP – TAF/FTC is non-inferior to TDF/FTC: results of phase 3 DISCOVER study
12 March 2019. Related: Conference reports, HIV prevention and transmission.
Dolutegravir can be given with 3HP to prevent TB without dose adjustment
12 March 2019. Related: Conference reports, PK and drug interactions, TB coinfection.
Double doses of darunavir given with rifampicin lead to high rates of hepatoxicity
12 March 2019. Related: Conference reports, PK and drug interactions, TB coinfection.
Shared housing compared to living alone: higher CD4, lower viral load and reduced inflammation in macaques
12 March 2019. Related: Conference reports, Coinfections and complications.
Selected webcasts at CROI 2019
12 March 2019. Related: Conference reports, PK and drug interactions.
i-Base Fit for Purpose report launched at CROI 2019
12 March 2019. Related: Supplements, Conference reports.
Pre-CROI Community HIV Cure Workshop 2019
12 March 2019. Related: Conference reports, Cure-related research.
27th International Workshop on HIV Drug Resistance and Treatment Strategies
20 February 2019. Related: Conference reports, Drug resistance.
Drug resistance in low- and middle-income countries
20 February 2019. Related: Conference reports, Drug resistance.
Glasgow HIV Congress (2018) – second reports
12 December 2018. Related: Conference reports.
Hepatitis C is an independent risk factor for preterm delivery in HIV positive women: data from a Warsaw cohort
12 December 2018. Related: Conference reports, Pregnancy.
Vertical transmission remains very low in UK and Ireland: update from the National Study of HIV in Pregnancy and Childhood
12 December 2018. Related: Conference reports, Pregnancy.
3rd HIV Research for Prevention Conference (R4P2018) – second reports
12 December 2018. Related: Conference reports, HIV prevention and transmission.
3D printing technology has potential to individualise production of vaginal rings
12 December 2018. Related: Conference reports, HIV prevention and transmission.
22nd International AIDS Conference (AIDS 2018) – final report
12 December 2018. Related: Conference reports.
No significant decrease in raltegravir free fraction during pregnancy
12 December 2018. Related: Conference reports, Paediatric care, PK and drug interactions.
Glasgow HIV Congress (2018)
13 November 2018. Related: Conference reports.
No additional neural tube defects with preconception dolutegravir: data from three birth outcome cohorts
13 November 2018. Related: Conference reports, Pregnancy, Paediatric care.
Insufficient data on risk of neural tube defects with exposure to elvitegravir or bictegravir exposure during preconception or first trimester
13 November 2018. Related: Conference reports, Pregnancy.
Viral dynamics of dolutegravir-based dual versus triple ART
13 November 2018. Related: Conference reports, Antiretrovirals.
Ibalizumab: 48-week phase 3 results in 27 participants with MDR HIV
13 November 2018. Related: Conference reports, Antiretrovirals.
Fostemsavir: 48-week phase 3 results from BRIGHTE study
13 November 2018. Related: Conference reports, Antiretrovirals.
Dolutegravir non-inferior to low dose efavirenz in real-life African study conducted in Cameroon
13 November 2018. Related: Conference reports, Antiretrovirals, Treatment strategies.
3rd HIV Research for Prevention Conference (R4P2018)
13 November 2018. Related: Conference reports, HIV prevention and transmission.
How to evaluate PrEP and vaccines: urgency for next generation compounds
13 November 2018. Related: Conference reports, HIV prevention and transmission, Cure-related research, Research studies.
Dual bNAb maintains viral suppression for median 21 weeks off-ART
13 November 2018. Related: Conference reports, Antiretrovirals, Treatment strategies.
Cabotegravir levels can be detected several years: PK tail to be covered by oral PrEP
13 November 2018. Related: Conference reports, Antiretrovirals.
3D imaging show HIV infection might establish within hours
13 November 2018. Related: Conference reports, HIV prevention and transmission.
bNAbs for HIV prevention: extended-release VRC01, AMP study, 10E8 safety signal and pan-clade challenges
13 November 2018. Related: Conference reports, PK and drug interactions, HIV prevention and transmission.
Why U=U does not cover breastfeeding
13 November 2018. Related: Conference reports, Paediatric care.
BHIVA Autumn Conference 2018
19 October 2018. Related: Conference reports.
Second case of potential HIV eradication
19 October 2018. Related: Conference reports, Cure-related research.
New UK PrEP guidelines 2018
19 October 2018. Related: Conference reports, HIV prevention and transmission.
Other selected talks at BHIVA Autumn 2018
19 October 2018. Related: Conference reports.
9th International Workshop on HIV and Ageing
19 October 2018. Related: Conference reports, Weight, diabetes, metabolic complications, Coinfections and complications.
Detectable viral load quadruples odds of recurrent falls in older men with HIV
19 October 2018. Related: Conference reports, Coinfections and complications.
More than 40% of HIV group has hepatic steatosis, regardless of age
19 October 2018. Related: Conference reports, Coinfections and complications.
Associations of loneliness with cognitive function and quality of life (QoL) among older adults living with HIV – 18% lonely quite often
19 October 2018. Related: Conference reports, Coinfections and complications.
Physical function worse in older women than men with HIV, despite better CD4 recovery
19 October 2018. Related: Conference reports, Coinfections and complications.
22nd International AIDS Conference (AIDS 2018) – third reports
19 September 2018. Related: Conference reports.
Dolutegravir twice daily is effective and tolerable with rifampicin: 48 week results from the INSPIRING study
19 September 2018. Related: Conference reports, TB coinfection.
TAF exposures during pregnancy and postpartum appear adequate but more data are needed
19 September 2018. Related: Conference reports, Pregnancy.
High rate of unintended pregnancy among HIV positive African women on ART
19 September 2018. Related: Conference reports, Women's health, Pregnancy.
22nd International AIDS Conference (AIDS 2018) – second reports
24 August 2018. Related: Conference reports.
Namibia close to achieving 90-90-90 targets
24 August 2018. Related: Conference reports, Treatment access.
Dolutegravir monotherapy: still no longer recommended in either research or clinical practice
24 August 2018. Related: Conference reports, Treatment strategies.